|Articles|June 1, 2001
- Pharmaceutical Executive-06-01-2001
- Volume 0
- Issue 0
Stocks: Catching the Market Blues
Author(s)Kevin Gopal
Buckinghamshire, UK-The pharma industry may be countercyclical, but it’s not immune to market trends. Nycomed Amersham recently postponed a partial US stock flotation of its life sciences company, ABBiotech, because of market weakness.
Advertisement
Articles in this issue
about 25 years ago
Industry Under Investigationabout 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
For Love of the Gameabout 25 years ago
Field of Dreamsabout 25 years ago
Workshop: Access Optionsabout 25 years ago
Emotion - The New Brand Integratorabout 25 years ago
Rx-to-OTC: Unwanted Attentionabout 25 years ago
Emotion - Biotech Renaissance Manabout 25 years ago
Relocation: Coming to Americaabout 25 years ago
Gathering LightAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
4
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
5